Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science

Zhang, Ruiwen; Nag, Subhasree

doi:10.1007/978-3-319-06151-1_16

Cited by 1 publication

(1 citation statement)

References 215 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and n ‐butylidenephthalide (isolated from Angelica sinensis (Oliv.) Diels) were reported as exhibiting MDM2 inhibition in brain cancer cell lines (N. M. Tsai et al, 2006; R. Zhang & Nag, 2014).…”

Section: Introductionmentioning

confidence: 99%

A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges

Pasdaran,

Grice,

Hamedi

2024

Drug Development Research

View full text Add to dashboard Cite

In 2021, the World Health Organization released the fifth edition of the central nervous system (CNS) tumor classification. This classification uses histopathology and molecular pathogenesis to group tumors into more biologically and molecularly defined entities. The prognosis of brain cancer, particularly malignant tumors, has remained poor worldwide, approximately 308,102 new cases of brain and other CNS tumors were diagnosed in the year 2020, with an estimated 251,329 deaths. The cost and time‐consuming nature of studies to find new anticancer agents makes it necessary to have well‐designed studies. In the present study, the pathways that can be targeted for drug development are discussed in detail. Some of the important cellular origins, signaling, and pathways involved in the efficacy of bioactive molecules against CNS tumorigenesis or progression, as well as prognosis and common approaches for treatment of different types of brain tumors, are reviewed. Moreover, different study tools, including cell lines, in vitro, in vivo, and clinical trial challenges, are discussed. In addition, in this article, natural products as one of the most important sources for finding new chemotherapeutics were reviewed and over 700 reported molecules with efficacy against CNS cancer cells are gathered and classified according to their structure. Based on the clinical trials that have been registered, very few of these natural or semi‐synthetic derivatives have been studied in humans. The review can help researchers understand the involved mechanisms and design new goal‐oriented studies for drug development against CNS malignancies.

show abstract

Section: Introductionmentioning

confidence: 99%